UnitedHealth stock price crash may prove ‘only the beginning': analyst warns

UnitedHealth Group's stock has fallen 50% since April, and Cavenagh Research projects further declines due to structural vulnerabilities. Key headwinds include a potential 5% revenue reduction per member from new Medicare Advantage rates in 2025, increased audit and compliance costs from CMS clawbacks, wage inflation impacting a large workforce, and a Department of Justice investigation into potential Medicare fraud; these factors erode UnitedHealth's defensive premium, leading Cavenagh to maintain a "Sell" rating despite the stock's discounted valuation and dividend yield.

Analysis

UnitedHealth Group's (NYSE: UNH) stock has experienced a significant downturn, plummeting approximately 50% since early April amid a confluence of severe challenges, prompting Cavenagh Research, a top-ranked analyst, to issue a "Sell" rating and warn of further potential declines. The company, once a blue-chip stalwart, is now perceived as entering a period of structural vulnerability. Key headwinds include pressures on its Medicare Advantage (MA) business, with a new rate notice for 2025 potentially reducing revenue per member by up to 5%, and anticipated significant "clawbacks" plus increased compliance costs stemming from Centers for Medicare & Medicaid Services (CMS) audits of MA contracts from 2018 to 2024. Furthermore, wage inflation poses a considerable threat to UnitedHealth's bottom line, given its large workforce exceeding 90,000 employees. Compounding these operational issues is a deepening regulatory overhang, exemplified by a U.S. Department of Justice investigation into potential Medicare fraud, which could inflict substantial legal and reputational damage. These factors are eroding UNH's historical defensive premium, and while the stock is trading at a notable discount to its historical multiples and offers a 2.79% dividend yield, Cavenagh Research advises caution, suggesting the recent 10% rebound from its year-to-date low does not negate the underlying risks and that the current stock price crash may be "only the beginning."

Key Decisions for Investors

• Investors should critically evaluate UnitedHealth's exposure to the identified structural headwinds, including sustained pressure on Medicare Advantage profitability, rising audit and compliance costs, wage inflation, and significant regulatory scrutiny from the Department of Justice, which collectively challenge the stock's historical defensive characteristics.
• Despite the current discounted valuation and 2.79% dividend yield, the strong "Sell" recommendation from Cavenagh Research and the potential for further share price erosion warrant a cautious stance; consider reducing exposure or deferring new investments until there is greater clarity on these multifaceted risks.
• Closely monitor developments concerning the 2025 Medicare Advantage rate finalization, the outcomes of CMS audits, and any progression in the DOJ investigation, as these will be critical determinants of UnitedHealth's future financial performance and stock trajectory.